Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vanda Salutari

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
Cancers|July 9, 2022
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological PatientsDaniela Pia Rosaria Chieffo, Letizia Lafuenti, Ludovica Mastrilli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot studyGabriella Ferrandina, Franco O Ranelletti, Francesco Legge, et al.
Expert Opinion on Pharmacotherapy|August 1, 2022
Recent progress in the use of pharmacotherapy for endometrial cancerElena Giudice, Vanda Salutari, Caterina Ricci, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 27, 2025
Long-term survival analysis of a randomized phase II study of front-line chemo-immunothe-rapy with carboplatin-paclitaxel using oreg-ovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002)Corrado Terranova, Vanda Salutari, Francesco Plotti, et al.
Critical Reviews in Oncology/Hematology|November 21, 2021
Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature reviewElena Giudice, Vanda Salutari, Caterina Ricci, et al.
Oncotargets and Therapy|July 23, 2014
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidenceFloriana Mascilini, Giulia Amadio, Maria Grazia Di Stefano, et al.
Cancers|March 25, 2022
PARP Inhibitors Resistance: Mechanisms and PerspectivesElena Giudice, Marica Gentile, Vanda Salutari, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 19, 2026
Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping reviewValentina Iacobelli, Floriana Camarda, Gloria Anderson, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 7, 2025
Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional studyMarco Tesei, Elisa Scarpelli, Maria Teresa Giudice, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 11, 2026
Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trialVanda Salutari, Claudia Marchetti, Elena Giudice, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Cancers|July 9, 2022
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological PatientsDaniela Pia Rosaria Chieffo, Letizia Lafuenti, Ludovica Mastrilli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot studyGabriella Ferrandina, Franco O Ranelletti, Francesco Legge, et al.
Expert Opinion on Pharmacotherapy|August 1, 2022
Recent progress in the use of pharmacotherapy for endometrial cancerElena Giudice, Vanda Salutari, Caterina Ricci, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 27, 2025
Long-term survival analysis of a randomized phase II study of front-line chemo-immunothe-rapy with carboplatin-paclitaxel using oreg-ovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002)Corrado Terranova, Vanda Salutari, Francesco Plotti, et al.
Critical Reviews in Oncology/Hematology|November 21, 2021
Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature reviewElena Giudice, Vanda Salutari, Caterina Ricci, et al.
Oncotargets and Therapy|July 23, 2014
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidenceFloriana Mascilini, Giulia Amadio, Maria Grazia Di Stefano, et al.
Cancers|March 25, 2022
PARP Inhibitors Resistance: Mechanisms and PerspectivesElena Giudice, Marica Gentile, Vanda Salutari, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 19, 2026
Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping reviewValentina Iacobelli, Floriana Camarda, Gloria Anderson, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 7, 2025
Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional studyMarco Tesei, Elisa Scarpelli, Maria Teresa Giudice, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 11, 2026
Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trialVanda Salutari, Claudia Marchetti, Elena Giudice, et al.
Pageof 11